Filing Flows › Comparisons › PLUR vs ATYR
Pluri vs aTYR Pharma: PLUR and ATYR compared
Pluri is the larger company: $335K of revenue in its latest quarter (Q4 FY26) against $190K for aTYR Pharma (Q3 2025).
Where the money goes: PLUR and ATYR
Pluri (PLUR) · Q4 FY26
Pluri, Q4 FY26: revenue $335K (-16% year over year), net loss $6.2M, operating cash flow −$4.4M. The chart follows the revenue to costs, profit and cash.
aTYR Pharma (ATYR) · Q3 2025
aTYR Pharma, Q3 2025: revenue $190K, net loss $25.7M, operating cash flow −$20.5M. The chart follows the revenue to costs, profit and cash.
| Pluri (PLUR) | aTYR Pharma (ATYR) | |
|---|---|---|
| Latest quarter | Q4 FY26 | Q3 2025 |
| Revenue | $335K | $190K |
| Revenue growth, Y/Y | -16% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$6.2M | −$25.7M |
| Operating cash flow | −$4.4M | −$20.5M |
Questions
Which is bigger, Pluri or aTYR Pharma?
Pluri is the larger company: $335K of revenue in its latest quarter (Q4 FY26) against $190K for aTYR Pharma (Q3 2025).
More: Pluri earnings · how Pluri makes money · aTYR Pharma earnings · how aTYR Pharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Sep 10, 2026; 10-Q filed Nov 6, 2025). Fiscal quarters can end on different dates. Not investment advice.